Aortic Valve Repair

Abstract

The present invention provides devices and methods for decalcifying an aortic valve. The methods and devices of the present invention break up or obliterate calcific deposits in and around the aortic valve through application or removal of heat energy from the calcific deposits.

Description

CROSS-REFERENCES TO RELATED APPLICATIONS[0001]This application is a divisional of U.S. patent application Ser. No. 11 / 299,246, filed Dec. 9, 2005, which claims the benefit of U.S. Provisional Application No. 60 / 635,275, filed Dec. 9, 2004; U.S. Provisional Application No. 60 / 662,764, filed Mar. 16, 2005; and U.S. Provisional Application No. 60 / 698,297, filed on Jul. 11, 2005; the entire contents of these applications are herein incorporated by reference for all purposes.BACKGROUND OF THE INVENTION[0002]Aortic valve stenosis is a common cardiac disease resulting in approximately 65,000 aortic valve replacement surgeries in the United States annually. Aortic valve stenosis can occur via several etiologies including rheumatic disease, congenital and degenerative calcific stenosis. In developing countries, rheumatic fever results in thickening and progressive immobility of the valve tissues. Calcific disease accounts for almost all of the cases of aortic stenosis in the United States an...

AI Technical Summary

Benefits of technology

[0015]In another aspect, the present invention provides a treatment catheter that comprises a mechanical element that can disrupt, e.g., mechanically break up, obliterate, and remove the calcific deposits in and around the aortic valve. Similar to the ultrasonic-based catheters, the catheter comprising the mechanical element may be steerable or otherwise articulable to allow the user to direct the distal end of the catheter grossly for initial placement, and then fine tune placement during treatment.

[0022]In addition, intravascular implants are contemplated by the present invention, including those placed within the valve annulus, supra annular, sub annular, or a combination thereof to assist in maintaining a functional valve orifice. Such implants may incorporate various pharamacological agents to increase efficacy by reducing restenosis, and otherwise aiding valve function. Implants may be formed of various metals, biodegradable materials, or combinations thereof.

Problems solved by technology

In developing countries, rheumatic fever results in thickening and progressive immobility of the valve tissues.

The presence and progression of this disease leads to a decreased functional area of the valve and dramatically reduced cardiac output.

Devices and techniques have suffered from only a modest ability to increase valve cross-sectional area, however.

Toward this end, other techniques such as direct surgical ultrasonic debridement of calcium deposits have had some success, but required an open surgical incision, thereby increasing the risk to the patient.

Although balloon dilatation offered patients a viable, less invasive alternative, it fell into disfavor in the early to mid 1990s primarily as a result of rapid restenosis of the valve post treatment.

The system is complex, requires upwards of 30 minutes of softening agent exposure time, and has resulted in complete AV block and emergency pacemaker implantation in some patients.

While the conventional methods have proven to be reasonably successful, the problem of aortic valve stenosis and subsequent restenosis after valvuloplasty or other intervention still requires better solutions.

Images